Drugs / ALXN2030
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05501717 | Aug 2022 → Oct 2025 overdue | — | Alexion Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06744647 | Mar 2025 → Oct 2027 expected | transplant rejection | Alexion Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALXN2030 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06744647 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT05501717 ↗ |